CorVel Q1 FY2027: Revenue Rises 11% to $260M, EPS Hits $0.63, $256M Cash with Zero Debt
CRVL sits 32% above its 52-week low of $44.83.
Summary
CorVel's Q1 FY2027 results show accelerating growth and profitability, backed by a debt-free balance sheet with over a quarter-billion in cash. The company continues to buy back stock aggressively.
Key Events · Earnings and Guidance · CRVL
-
Revenue Climbs 11% to $260M
Driven by growth across Patient Management and Network Solutions, Q1 FY2027 revenue reached $260 million, up from $235 million in the prior-year quarter.
-
EPS Jumps 21% to $0.63
Reflecting improved operating leverage and a lower share count from buybacks, diluted earnings per share rose to $0.63 from $0.52.
-
Gross Margin Expands to 26%
Gross profit increased 19% to $67.8 million, with gross margin improving from 24% to 26%, indicating better cost management and mix.
-
Cash Hoard Grows to $256M, Debt-Free
The quarter ended with $255.9 million in cash and equivalents, no borrowings, and total assets of $689.7 million.
Analysis · CRVL · Finance
A strong start to fiscal 2027 saw CorVel deliver double-digit revenue and earnings growth, expanding margins, and a fortress balance sheet. The 11% revenue increase and 21% EPS jump signal continued momentum in its core workers' compensation and liability markets. With $256 million in cash and zero borrowings, the company has ample firepower for further buybacks or strategic investments. The $21.8 million in quarterly repurchases underscores management's commitment to returning capital, though the recent insider selling pattern warrants monitoring.
At the time of this filing, CRVL was trading at $59.10 on NASDAQ in the Finance sector, with a market capitalization of approximately $3B. The 52-week trading range was $44.83 to $93.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.